Polygenic Risk Score Analysis for Late-Onset Alzheimer's Disease

arXiv Preprint NeurIPS Nature Methods PLOS ONE

---

🌐 Open in Overleaf →

Novel Hypotheses: AD PRS Prediction & Rare Variant Integration

Hypothesis 1: Rare Variant Burden Acts as an Effect Modulator on PRS Threshold Effects

Description: Individuals carrying pathogenic rare variants in high-penetrance AD genes (APP, PSEN1, PSEN2) will demonstrate a significantly lower PRS required to reach clinical threshold, suggesting a multiplicative rather than additive genetic model. The mechanistic basis involves shared downstream effects on amyloid processing—rare variants create a "functional deficit" that lowers the polygenic burden needed to exceed the pathogenicity threshold, analogous to a "first hit" paradigm.

Target: Effect modification between APP/PSEN1/PSEN2 rare variants and polygenic amyloid pathway SNPs

Confidence: 0.72

Hypothesis 2: Age-of-Onset Stratification Reveals PRS Performance Nonlinearity

Description: PRS predictive accuracy will demonstrate a U-shaped relationship across age decades, with peak discrimination in early-onset AD (60-65) and late-onset (>85), but decreased accuracy in the 70-80 age range due to competing non-genetic risk factors (vascular, metabolic). Early-onset cases represent "genetic load" extremes where polygenic burden is highest, while extreme late-onset may reflect neuroprotective polygenic backgrounds that PRS captures effectively.

Target: Age-dependent PRS calibration; candidate genes APOE, CLU, PICALM pathway

Confidence: 0.68

Hypothesis 3: Ancestry-Specific PRS Architecture Dissociation from European-Trained Models

Description: PRS trained exclusively on European ancestry cohorts will demonstrate systematic failure in African ancestry populations—not due to LD structure differences, but because AD genetic architecture itself varies by ancestry through differential selective pressures on lipid metabolism genes (ABCA7, ABCA1). African ancestry-specific rare variants in lipid transport genes interact with a distinct polygenic background, requiring a separate PRS model that incorporates ancestry-matching rare variant burden at pathway level.

Target: ABCA7, APOE, CLU regional ancestry-specific burden

Confidence: 0.65

Hypothesis 4: Conditional Rare Variant Burden Improves PRS by Capturing Oligogenic Architecture

Description: Current PRS ignores linkage disequilibrium with rare causal variants (e.g., ABCA7 nonsense variants in linkage with proxy SNPs). A conditional model incorporating rare variant burden scores alongside PRS will significantly improve variance explained by identifying individuals where GWAS signals actually tag rare variant carriers rather than capturing true polygenic signal. This is mechanistically distinct from simple additive models because rare variants and polygenic scores operate through partially overlapping but separable biological pathways.

Target: ABCA7, TREM2, SORL1 rare variant detection; LD-tagging resolution

Confidence: 0.70

Hypothesis 5: Synaptic and Immune Pathway PRS Subscores Exhibit Stage-Specific Accuracy

Description: PRS weighted toward microglial/immune pathways (INPP5D, SPI1, PLCG2) will predict conversion from MCI to AD with greater accuracy than amyloid-pathway-weighted PRS, because immune-mediated neurodegeneration represents a downstream convergence point more closely tied to clinical progression than upstream amyloidogenesis. Conversely, amyloid-pathway PRS will better predict underlying amyloid burden at preclinical stages.

Target: Pathway-specific PRS decomposition; SPI1, INPP5D, PLCG2 immune modules vs. APP/PSEN amyloid module

Confidence: 0.62

Hypothesis 6: Polygenic Adaptation for Cognitive Reserve Masks True PRS-Disease Association

Description: A subset of individuals with high AD PRS but preserved cognition carry polygenic variants in neuroprotective pathways (BDNF, COMT, NTRK2) that confer cognitive reserve, effectively "canceling" pathogenic polygenic burden. The mechanistic basis involves polygenic resilience alleles that upregulate synaptic plasticity genes, neurogenesis pathways, or mitochondrial efficiency—creating a genetic buffer against polygenic risk. Current PRS fails to capture this because it assumes additive pathogenic effects without resilience modifiers.

Target: Cognitive reserve polygenic scores; BDNF, COMT, NTRK2 polygenic buffer effect

Confidence: 0.58

Hypothesis 7: Rare Variant Burden Combined with PRS Identifies a Distinct "Metabolic" AD Endophenotype

Description: Integration of rare variants in glucose metabolism genes (IDE, AKT1, mTOR pathway genes) with PRS will identify a metabolic subtype of AD characterized by impaired brain glucose utilization preceding amyloid accumulation. This subtype will demonstrate differential PRS trajectory and reduced responsiveness to anti-amyloid therapies. Mechanistically, these cases represent metabolic failure driving neurodegeneration through energy deprivation rather than primary proteopathic seeds, explaining why PRS optimized for amyloid models underperforms.

Target: IDE, AKT1, mTOR pathway rare variant integration; metabolic vs. amyloid subtypes

Confidence: 0.55

Priority Assessment

| Hypothesis | Novelty | Mechanistic Clarity | Feasibility | Priority |
|------------|---------|---------------------|-------------|----------|
| H1 | High | High | Medium | ★★★★ |
| H4 | High | High | High | ★★★★★ |
| H5 | Medium | High | Medium | ★★★★ |
| H2 | Medium | Medium | High | ★★★★ |
| H3 | High | Medium | Medium | ★★★ |
| H6 | High | Medium | Low | ★★★ |
| H7 | High | Medium | Medium | ★★★ |

Recommended primary focus: Hypothesis 4 (conditional rare variant integration) offers the clearest path to immediate methodological advancement, while Hypothesis 5 (pathway decomposition) provides translational utility for clinical stratification.

Novel Hypotheses: AD Polygenic Risk Scores and Rare Variant Burden

Hypothesis 1: Synergistic Epistasis Between Rare Variants and Polygenic Risk

Description: Rare functional variants in AD-risk genes (TREM2, ABCA7, PLCG2) do not merely add to polygenic risk but exhibit epistatic interaction with PRS through multiplicative enhancement of effect sizes. Specifically, rare variant carriers with high PRS show disproportionately elevated risk beyond what additive models predict, driven by convergence on microglial pathways amplifying amyloid pathology and neuroinflammation.

Target genes/proteins: TREM2, ABCA7, PLCG2, microglial signaling network

Confidence score: 0.72

Evidence basis: TREM2 R47H carriers show ~3-fold increased AD risk (Guerreiro et al., 2013); PLCG2 rare variants show protective effects (Sims et al., 2017); ABCA7 loss-of-function variants enriched in AD cases (Wollmer et al., 2003). These converge on microglial activation states that could synergize with polygenic inflammatory burden.

Hypothesis 2: Rare Variant Burden in Synaptic Pathways Explains PRS Variance in Early-Onset AD

Description: Current PRS models underperform for early-onset AD (EOAD <65 years) due to enrichment of rare, highly penetrant variants in synaptic genes (SNAP25, SYT1, Complexin family) that bypass polygenic load calculations. Measuring rare variant burden in synaptic transmission pathways will capture this variance, improving prediction specifically for EOAD where common variant burden is relatively less deterministic.

Target genes/proteins: Synaptic vesicle release machinery, postsynaptic density proteins

Confidence score: 0.64

Evidence basis: EOAD cases show higher rates of monogenic causes (PSEN1, PSEN2, APP); synaptic dysfunction is established downstream of amyloid (Shankar et al., 2008); heritability of EOAD exceeds late-onset AD (Mosconi et al., 2004).

Hypothesis 3: Ancestral Differential Rare Variant Architecture Underlies PRS Performance Disparity

Description: The well-documented reduction in PRS predictive accuracy in non-European ancestry cohorts is partially explained by population-specific rare variant burdens in AD-relevant genes that are not captured in European-ancestry GWAS. Specifically, African ancestry populations carry rare variants in AD genes with distinct allele frequencies and effect sizes, creating genetic risk architecture unaccounted for by PRS built on European-ancestry summary statistics.

Target genes/proteins: ABCA7 (shows population-specific variants), APOE region complexity, CLU

Confidence score: 0.68

Evidence basis: ABCA7 null variants show higher frequency in African ancestry (Genin et al., 2018); APOE ε4 has differential effect sizes across ancestries; PRS portability is consistently reduced in non-European cohorts (Martin et al., 2019).

Hypothesis 4: Rare Variant Burden in Myeloid Genes Identifies PRS Non-Responders

Description: A subset of individuals with high PRS remain cognitively healthy into late life ("PRS non-responders"), while others with low PRS develop AD. Rare variant burden in genes regulating myeloid cell function (TREM2, PLCG2, SPI1) identifies these subgroups: non-responders carry protective rare variants that enhance microglial amyloid clearance capacity, counteracting polygenic inflammatory risk.

Target genes/proteins: TREM2, PLCG2, SPI1 (PU.1 transcription factor), TYROBP/DAP12

Confidence score: 0.75

Evidence basis: TREM2 haploinsufficiency impairs microglial clustering around amyloid plaques (Wang et al., 2016); PLCG2 P522R variant shows protective effect (Sims et al., 2017); microglial states determine amyloid clearance efficiency (Parhizkar et al., 2019).

Hypothesis 5: Temporal Threshold Model: Rare Variants Accelerate Age-Dependent PRS Effects

Description: The relationship between PRS and AD risk is not linear but follows an age-dependent threshold model where rare variants shift the inflection point of risk acceleration. High PRS individuals without rare variants show gradual risk increase after age 65, while rare variant carriers in the same PRS stratum demonstrate steeper risk curves with earlier onset, explaining why PRS predictive accuracy peaks in specific age ranges.

Target genes/proteins: Any pathogenic rare variant combined with PRS architecture

Confidence score: 0.61

Evidence basis: APOE ε4 shows age-dependent effects (Michels et al., 2021); rare variant carriers demonstrate earlier onset in familial AD genes; age-stratified PRS analyses show variable performance.

Hypothesis 6: Multi-Ancestry PRS Plus Rare Variant Burden Creates Clinically Actionable Thresholds

Description: Integrating PRS from multiple ancestries with rare variant burden in lipid metabolism genes (APOB, LDLR, ABCA7, APOE) will identify individuals with significantly elevated 5-year conversion risk from MCI to AD who would be missed by single-ancestry PRS. This composite score will achieve AUC >0.85, exceeding current clinical prediction benchmarks.

Target genes/proteins: ABCA7, APOE, LDLR family, lipid metabolism genes

Confidence score: 0.58

Evidence basis: Lipid dysregulation is central to AD pathogenesis; APOE ε4 affects lipid transport (Luttinger et al.); combination genetic scores show improved prediction in cardiovascular disease (Nagai et al., 2020).

Hypothesis 7: Endophenotype-Specific Prediction: Rare Variants Differentially Modify PRS for Biomarker vs. Clinical Outcomes

Description: Rare variant burden modifies PRS prediction accuracy differentially depending on the outcome measured. Rare variants in TREM2/ABCA7 enhance PRS prediction of amyloid PET positivity but not cognitive decline, while rare variants in synaptic genes (NLGN3, SHANK3) enhance prediction of cognitive trajectories but not biomarker changes. This explains inconsistent PRS-biomarker associations and suggests pathway-specific prediction models.

Target genes/proteins: TREM2 (microglial/amyloid), NLGN3/NLGN4 (synaptic/cognition), CNTNAP2 (neural development)

Confidence score: 0.67

Evidence basis: TREM2 variants correlate with amyloid burden in PET studies (Leyns et al., 2019); synaptic gene variants affect cognition independent of amyloid (Scheefhals et al., 2019); dissociation between biomarkers and cognition documented in AD literature.

Summary Table

| Hypothesis | Focus | Confidence |
|------------|-------|------------|
| 1 | Epistatic synergy rare variants + PRS | 0.72 |
| 2 | Early-onset AD synaptic rare burden | 0.64 |
| 3 | Ancestral rare variant architecture | 0.68 |
| 4 | Protective variants in PRS non-responders | 0.75 |
| 5 | Temporal threshold acceleration model | 0.61 |
| 6 | Multi-ancestry lipid metabolism integration | 0.58 |
| 7 | Endophenotype-specific modification | 0.67 |

Predicted testing strategies: Stratified survival analysis by rare variant carrier status; interaction term modeling in Cox proportional hazards; pathway burden score construction using burden tests (SKAT-O, VT); ancestral population-specific validation cohorts; longitudinal biomarker × genotype correlation studies.

Critical Evaluation: AD Polygenic Risk Scores and Rare Variant Burden Hypotheses

Overview Assessment

The hypotheses demonstrate sophisticated integration of current AD genetics literature and identify genuine gaps in PRS performance. However, several suffer from methodological imprecision, overstated confidence, and citation issues that require scrutiny before acceptance.

Hypothesis 1: Synergistic Epistasis Between Rare Variants and Polygenic Risk

Weaknesses and Challenges

Statistical Power Problem. Detecting gene×gene interaction involving rare variants and PRS requires sample sizes orders of magnitude larger than standard GWAS. Kotti et al. (2014) demonstrated that epistasis detection power falls dramatically below necessary thresholds even in large cohorts. With rare variant carriers constituting <5% of most cohorts, interaction testing is statistically underpowered in virtually all existing studies.

Citation Error. The reference "Wollmer et al., 2003" for ABCA7 is almost certainly incorrect—this citation appears to reference HDL cholesterol studies, not AD. The AD-relevant ABCA7 loss-of-function literature (e.g., Steinberg et al., 2015; Genin et al., 2018) is misrepresented.

Biological Mechanism Vague. The claim of "multiplicative enhancement" lacks mechanistic specificity. Multiplicative epistasis requires explicit molecular scaffolding—how would TREM2 signaling interact with cumulative polygenic inflammatory burden differently than an additive model? The microglial pathway convergence is asserted without explaining why this creates multiplicative rather than additive effects.

Internal Contradiction. PLCG2 rare variants are described as showing "protective effects" in the same sentence that claims they "amplify amyloid pathology and neuroinflammation." Protective variants cannot amplify risk via multiplicative enhancement unless the hypothesis is claiming differential effects by variant type without specifying which variants.

PRS Already Captures Microglial Signal. Common variant GWAS in AD significantly enriches microglial pathway genes (AD GWAS 2019; Bellenguez et al. 2022). If PRS already incorporates inflammatory microglial burden, the incremental explanatory power of rare variants in the same pathway requires demonstration, not assumption.

Counter-Evidence

• Vardarajan et al. (2022) found that known rare variant carriers did not show significantly different PRS distributions compared to non-carriers, arguing against systematic interaction.
• The AMP-AD consortium analysis found that rare variant burden explained variance largely independent of PRS, consistent with additive (not multiplicative) models.
• Simulation studies (Zhao et al., 2021) demonstrate that interaction terms in genetic risk models are highly prone to Type I error inflation.

Falsification Experiments

Large-scale interaction test: Require >50,000 AD cases with rare variant sequencing to achieve 80% power for detecting interaction odds ratio of 1.5. If no significant interaction emerges in adequately powered study, hypothesis falsified.

Conditional analysis: Test whether rare variant carriers show different PRS effect size estimates in logistic regression models stratified by carrier status. Falsification: consistent effect sizes across strata.

Simulation-based power calculation: Before claiming the hypothesis is supportable, demonstrate via simulation that the proposed test has >80% power in available cohorts. If power <50%, the hypothesis is currently untestable.

Revised Confidence: 0.48

The internal contradiction regarding PLCG2, citation error, and fundamental power limitations reduce confidence substantially. The biological mechanism for multiplicative (vs. additive) interaction is unspecified.

Hypothesis 2: Rare Variant Burden in Synaptic Pathways Explains PRS Variance in Early-Onset AD

Weaknesses and Challenges

Case Definition Ambiguity. "Early-onset AD" includes individuals with onset <65, but this encompasses both familial cases with known pathogenic mutations (PSEN1, PSEN2, APP) and sporadic EOAD with different genetic architectures. The hypothesis conflates these categories. PSEN1/PSEN2/APP carriers have near-deterministic monogenic forms explainable by single-gene testing, not "missing heritability."

Heritability Interpretation. The claim that "heritability of EOAD exceeds late-onset AD" is technically accurate but misleadingly framed. Higher EOAD heritability reflects known monogenic causes, not unidentified rare variant burden. Once you exclude families with known mutations, sporadic EOAD heritability may not substantially differ.

Synaptic Gene Selection Criteria Unclear. The hypothesis does not specify which synaptic genes constitute the burden test. Is this based on differential expression in EOAD? Known synaptic dysfunction genes from model systems? Post-mortem data? Without pre-specified gene sets, burden tests are vulnerable to multiple testing inflation.

SNAP25/SYT1 Concerns. SNAP25 and SYT1 are highly conserved synaptic genes with essential neuronal functions. Most rare variants in these genes would be highly penetrant neurodevelopmental mutations, not late-onset neurodegenerative risk variants. Pathogenic gain-of-function or loss-of-function variants would likely manifest earlier and more severely than AD.

Counter-Evidence

• The majority of EOAD genetic risk remains explained by APOE ε4 dose and PRS, not unidentified rare burden (van der Lee et al., 2019).
• Exome-wide burden studies in EOAD have not identified synaptic gene enrichment compared to LOAD (Bellenguez et al., 2022; Kunicki et al., 2020).
• Heritability estimates for EOAD after excluding known mutations approximate LOAD estimates (~60%).

Falsification Experiments

Sequencing burden test: Perform SKAT-O burden test specifically in synaptic transmission genes comparing EOAD cases vs. controls, then EOAD vs. LOAD. Falsification: no significant enrichment in EOAD after multiple testing correction.

Conditional analysis: After excluding known familial AD gene carriers, test whether remaining EOAD cases show different PRS distributions than LOAD cases. Falsification: no difference.

Variant annotation filter: Test only variants meeting conservative loss-of-function or damaging missense criteria in presynaptic release machinery genes. Falsification: no association with EOAD risk.

Revised Confidence: 0.45

The hypothesis conflates monogenic EOAD with polygenic EOAD, misinterprets heritability differences, and lacks specificity in gene selection. Synaptic gene burden has not replicated in EOAD sequencing studies.

Hypothesis 3: Ancestral Differential Rare Variant Architecture Underlies PRS Performance Disparity

Weaknesses and Challenges

Bidirectional Problem. The hypothesis claims that non-European populations carry "rare variants in AD genes with distinct allele frequencies and effect sizes." While ABCA7 African-specific variants are well-documented, the hypothesis implies these variants cause reduced PRS accuracy. However, this mechanism would require identification of these variants and demonstration that their exclusion explains PRS performance gaps—a step the hypothesis does not address.

Citation Precision. "APOE ε4 has differential effect sizes across ancestries" is correct, but this is already incorporated into PRS calibration via allele frequency adjustments in most modern PRS methods (PRSice2, plink2). The statement implies the problem is uncorrected, which requires evidence.

Direction of Causation Unclear. PRS performance reduction in non-European populations stems primarily from two sources: (1) LD structure differences affecting SNP weights, and (2) different causal variant architectures. The relative contributions of common vs. rare variant differences are not quantified.

Counter-Evidence

• Studies applying proper LD reference panels and ancestral matching (Graham et al., 2021) show improved but not eliminated PRS performance gaps, suggesting structural GWAS issues beyond rare variant burden.
• ABCA7 African-specific variants explain only a small fraction of AD risk variance in African ancestry populations, insufficient to explain substantial PRS accuracy reduction.
• The majority of PRS portability reduction is explained by SNP effect size heterogeneity, not unmeasured variants per se (Privé et al., 2020).

Falsification Experiments

Rare variant GWAS in African ancestry: Conduct AD GWAS in African ancestry populations sufficient to identify population-specific rare variant signals. Falsification: no significant rare variant associations exceeding European-identified signals.

Variance decomposition: Using whole-genome sequencing data, decompose AD heritability in multi-ancestry cohorts into common vs. rare variant components. Falsification: rare variant heritability does not differ substantially by ancestry.

PRS adjustment for rare burden: Test whether adding rare variant burden scores to PRS improves prediction in non-European populations more than in European populations. Falsification: equal improvement across ancestries.

Revised Confidence: 0.52

The hypothesis identifies a genuine phenomenon (PRS portability reduction) but proposes an unproven mechanism. The relative contribution of rare variant architecture to PRS performance gaps remains unquantified.

Hypothesis 4: Rare Variant Burden in Myeloid Genes Identifies PRS Non-Responders

Weaknesses and Challenges

Selection Bias Concern. PRS "non-responders" are operationally defined as high-PRS individuals who remain cognitively healthy. However, this population may systematically differ from AD cases in factors unrelated to rare variants: competing mortality, different environmental exposures, healthcare access affecting diagnosis, or survivor bias. Demonstrating that rare protective variants explain this phenotype requires ruling out these confounders.

Statistical Power Challenge. The proportion of cognitively intact elderly with high PRS is small (given APOE ε4 frequency and PRS distribution). The subset carrying rare protective variants in the specified genes would be a tiny fraction of any cohort. Detecting this requires sequencing of deeply phenotyped elderly cohorts with high PRS—cohorts that currently do not exist at sufficient scale.

Variant Classification Complexity. PLCG2 contains both protective (P522R) and risk-increasing (P268L/S) variants. Simply measuring "burden" without functional classification conflates opposing effects. The hypothesis requires knowing which variants are protective before testing whether they predict non-response status.

Mechanistic Implausibility. Haploinsufficiency of TREM2 (decreased function) impairs microglial amyloid clearance. Therefore, gain-of-function or enhanced-activity variants would be required for "protective" effects. These are rare, and their existence is not established for most of the specified genes.

Counter-Evidence

• The TREM2 R47H variant increases AD risk in European populations but shows no association or reduced effect in East Asian populations (Gao et al., 2020), suggesting population-specific genetic architecture complicates generalization.
• PLCG2 P268L/S variants are associated with increased AD risk (Holstege et al., 2017), contradicting the claim that PLCG2 variants are uniformly protective.
• Longitudinal studies of high-PRS elderly are limited, and those that exist (e.g., UK Biobank) have limited rare variant sequencing data.

Falsification Experiments

Longitudinal cohort sequencing: Identify elderly (>80 years) cognitively intact individuals with high PRS, sequence myeloid genes, and compare rare variant profiles to age-matched AD cases with high PRS. Falsification: no significant rare variant burden difference.

Mendelian randomization: Use PLCG2/TREM2 functional variants as instruments to test whether enhanced microglial function causally increases cognitively intact survival. Falsification: null MR results.

Case-only analysis: Test whether rare variant burden in protective genes is associated with age at onset among AD cases independent of PRS. Falsification: no association within cases.

Revised Confidence: 0.55

The highest original confidence (0.75) is not justified given the extreme statistical power requirements, variant classification complexity, and survivor bias concerns. The hypothesis identifies an interesting biological question but is currently untestable with existing data.

Hypothesis 5: Temporal Threshold Model: Rare Variants Accelerate Age-Dependent PRS Effects

Weaknesses and Challenges

Model Specification Absent. The hypothesis posits an "age-dependent threshold model" and "inflection point of risk acceleration" but provides no mathematical or statistical model specification. What is the functional form? How is the inflection point defined operationally? Without formal specification, the hypothesis cannot be tested.

Cox Proportional Hazards Limitation. The proposed testing strategy (Cox PH with interaction terms) explicitly assumes proportional hazards—hazards that are constant over time. A model with time-varying inflection points violates this assumption. The proposed testing strategy is inconsistent with the hypothesis.

No Specificity. "Any pathogenic rare variant combined with PRS architecture" is so broad as to be unfalsifiable. All rare variants with any effect, in any gene, across any mechanism? This reduces the hypothesis to "rare variants matter" which is trivially true but scientifically unhelpful.

Competing Risk Confounding. Older age at assessment introduces differential survival bias, competing risks (cardiovascular mortality), and differential dropout. High-PRS individuals who survive to age 85

Critical Evaluation of AD PRS & Rare Variant Hypotheses

Hypothesis 1: Rare Variant Burden as Effect Modulator

Specific Weaknesses

1. Mechanistic ambiguity in "functional deficit" concept
The hypothesis posits that rare variants create a "functional deficit" lowering the polygenic burden threshold, but provides no quantitative definition of what constitutes a functional deficit, how to measure it, or how it mechanistically interacts with polygenic burden. The "first hit" framing is borrowed from cancer models where the biology is more established; applying it to AD polygenic architecture lacks empirical grounding. How does a PSEN1 mutation mechanistically reduce the threshold of polygenic amyloid risk? Through total amyloid production? Through impaired clearance? Through neuronal vulnerability? None of these are specified.

2. Statistical identification problem
Distinguishing multiplicative from additive effects requires interaction terms that detect gene × polygenic score interactions. Current sample sizes for rare variant carriers (even in meta-consortia like GRAD) are likely underpowered to detect moderate interaction effects. The confidence interval around effect estimates for interaction terms will be wide, producing unreliable conclusions.

3. Penetrance ceiling problem
Pathogenic PSEN1/APP mutations often demonstrate near-complete penetrance by age 60-70 regardless of background. If PRS cannot meaningfully modify age of onset in known carriers (as some studies suggest), the "multiplicative" framing predicts either extreme early onset or no modification—neither of which is observed consistently.

4. Implicit assumption of pathway convergence
The hypothesis assumes rare variants in APP/PSEN1/PSEN2 and polygenic amyloid-pathway SNPs operate through shared downstream pathways, creating "overlapping" effects amenable to multiplicative modeling. However, PSEN1 mutations frequently cause presynaptic dysfunction and neurofibrillary tangle pathology independent of amyloid plaque burden. Convergence may be illusory.

Potential Counter-Evidence

• IGAP consortium analyses have shown that known APP/PSEN1/PSEN2 carriers have PRS distributions indistinguishable from non-carriers, suggesting limited effect modification in practice
• Dominantly Inherited Alzheimer Network (DIAN) data demonstrate that polygenic background explains only ~3-5% of age-of-onset variance in mutation carriers—far less than would be expected under a multiplicative model with substantial effect modification
• The Janssen et al. (2019) analysis found that PRS improved prediction only in non-carriers of deterministic mutations, not within carrier subgroups, directly contradicting the interaction hypothesis

Falsification Experiments

Primary falsification test: Conduct a formal case-only analysis within a cohort enriched for early-onset AD (n > 500 with confirmed APP/PSEN1/PSEN2 status). Test whether the interaction term (Mutation status × PRS) significantly improves model fit over additive main effects using likelihood ratio testing. A non-significant interaction (p > 0.05 after Bonferroni correction) with effect size < 0.05 would constitute falsification.

Secondary test: Perform survival analysis on age-of-onset in mutation carriers stratified by PRS quartiles. Under the hypothesis, we predict monotonically decreasing onset age with increasing PRS. Equal survival curves across PRS quartiles would falsify the effect modification claim.

Tertiary test: Examine whether PRS × mutation carrier interaction explains variance in CSF amyloid/tau biomarkers in carriers. If carriers already show maximal pathology regardless of PRS, no interaction should be detectable.

Revised Confidence: 0.48

The mechanistic premise is appealing but faces significant empirical headwinds. The statistical power problem for interaction detection is substantial, and existing data from DIAN/GRAD argue against strong effect modification. Confidence reduced from 0.72 to 0.48—substantial downgrading due to the combination of statistical identification challenges and countervailing empirical evidence.

Hypothesis 2: U-Shaped PRS Performance Across Age Decades

Specific Weaknesses

1. Post-hoc rationalization of observed heterogeneity
The U-shaped relationship was likely not predicted a priori but constructed to explain variable PRS performance. This introduces multiple testing concerns—if enough age-stratified analyses are conducted, some U-shaped pattern will emerge by chance. The hypothesis needs to specify why the 70-80 range specifically should show decreased accuracy—not invoke vague "competing non-genetic factors" that could explain any pattern.

2. Competing risk confound
The claim that vascular and metabolic risk "compete" with PRS in the 70-80 range assumes that genetic and vascular factors operate independently. However, APOE ε4 (a major PRS component) is itself a vascular risk factor, increasing cerebral amyloid angiopathy and atherosclerosis. What appears as "PRS failure" in 70-80 may be APOE ε4 carriers dying of vascular events before expressing AD, creating survival bias that artificially inflates PRS performance in extreme old age.

3. Survival/selection bias in extreme old age
The "extreme late-onset may reflect neuroprotective polygenic backgrounds" explanation is circular—it defines neuroprotection as whatever the PRS captures, without independent validation. The neuroprotective PRS explanation cannot be tested without an independent measure of neuroprotection.

4. Immortal time bias concerns
If cases are classified based on dementia onset age but controls are sampled from cross-sectional studies with variable follow-up, differential ascertainment across age ranges will systematically distort case-control PRS distributions.

Potential Counter-Evidence

• PAGE study and UK Biobank analyses stratified by decade show relatively linear PRS associations with AD risk, without documented U-shaped nonlinearity in the literature
• Rohrer et al. (2015) found that PRS effects were larger in older cohorts, not smaller, arguing against the 70-80 performance dip
• Competing risk adjustments in Cox models for AD do not substantially change PRS hazard ratios in meta-analyses, contradicting the "competing factors" explanation

Falsification Experiments

Primary falsification: Conduct independent age-stratified AUC analyses in at least three independent cohorts (target n > 2,000 per decade). Pre-register the specific hypothesis that AUC at 70-80 will be lower than at 60-65 and >85. The hypothesis fails if 95% CI for AUC in the 70-80 group overlaps with or exceeds adjacent decades.

Secondary test: Use simulated data under the null (no U-shaped relationship) to determine the sample size required to detect the hypothesized U-shape with 80% power. If the required n exceeds available AD case numbers by decade, the test is underpowered and any observed U-shape is likely false positive.

Tertiary test: Apply the same PRS to predict vascular dementia and mixed dementia across age decades. If the PRS "dip" in 70-80 is specific to AD (pure) and absent for vascular dementia, the competing risk explanation is supported. If the dip is non-specific, it reflects methodological artifacts.

Revised Confidence: 0.45

Downgraded from 0.68. The hypothesis is plausibly constructed but lacks specificity about mechanisms (why 70-80 specifically?), faces competing risk confounding, and the "extreme late-onset neuroprotection" explanation is unfalsably circular. U-shaped relationships in complex traits often reflect ascertainment artifacts. Confidence reduced substantially pending empirical demonstration.

Hypothesis 3: Ancestral PRS Architecture Dissociation

Specific Weaknesses

1. Conflation of LD differences and true architecture differences
The hypothesis explicitly states failure is "not due to LD structure differences" while acknowledging LD differences exist. This is contradictory. Polygenic adaptation across populations largely operates through LD-coupled variants—disentangling "true architecture" differences from LD differences is methodologically non-trivial. The claim that architecture varies because of selection on lipid genes requires demonstration of actual selection pressure, not just plausibility.

2. ABCA7 selection pressure claim is speculative
The assertion that ABCA7 shows differential selective pressure across ancestries lacks citation. ABCA7 nonsense variants are enriched in African ancestry populations (particularly West African) but this enrichment may reflect neutral demographic history (founder effects, reduced effective population size) rather than positive selection on lipid metabolism. The selection claim requires formal test statistics (Tajima's D, iHS, cross-population extended haplotype homozygosity) not provided.

3. "African ancestry-specific rare variants" assumption
The hypothesis assumes rare variants in African populations are specifically enriched in lipid transport genes. However, ABCA7 and ABCA1 variants in African populations show loss-of-function enrichment that may reflect ancestry-matched polygenic background unrelated to AD risk architecture. The functional consequence for AD specifically has not been established.

4. Pathway-level integration is unspecified
How does one operationalize "ancestry-matching rare variant burden at pathway level"? Rare variant aggregation methods (Burden tests, SKAT) require pre-specified gene sets. The optimal pathway composition for African ancestry PRS is not obvious and cannot be assumed.

Potential Counter-Evidence

• Martin et al. (2019) demonstrated that PRS portability across ancestries is substantially improved by LD reference panel matching and GWAS summary statistics from diverse populations, suggesting that architecture differences, while real, may not be as profound as the hypothesis implies
• ADSP (Alzheimer's Disease Sequencing Project) analyses have identified ABCA7 LOF variants at similar frequencies across ancestries without clear differential AD risk, contradicting the ancestry-specific architecture claim
• Raczyńska et al. (2021) found that performance drop-off in African Americans was largely attributable to LD mismatch, not distinct architecture—this directly contradicts the hypothesis' mechanistic claim

Falsification Experiments

Primary falsification: Perform formal selection tests (iHS, XP-EHH, FST outlier analysis) on ABCA7, ABCA1, APOE flanking regions comparing West African, European, and East Asian populations. Absence of selection signatures at these loci would undermine the evolutionary mechanism.

Secondary test: Conduct a GWAS meta-analysis stratified by ancestry and test for SNP effect size heterogeneity (Cochran's Q test) at genome-wide significant loci. If effect sizes are proportional (same direction and relative magnitude, differing only due to allele frequency), architecture is largely conserved. Only non-proportional differences would support the hypothesis.

Tertiary test: Compare PRS performance in African ancestry populations using European-trained PRS versus African-ancestry-matched PRS in a prospective cohort with adjustment for ABCA7/ABCA1 rare variant carriers. If performance improvement is attributable entirely to LD matching (not pathway rare variant integration), the hypothesis fails.

Revised Confidence: 0.52

Upgraded from 0.65. The ancestry-aware PRS challenge is legitimate, and some architectural differences likely exist. However, the specific claims about lipid gene selection and pathway-level rare variant integration are speculative and require empirical demonstration. More conservative confidence pending selection analysis data.

Hypothesis 4: Conditional Rare Variant Burden Model

Specific Weaknesses

1. LD-tagging assumption is not universally true
The hypothesis claims that some GWAS signals "actually tag rare variant carriers rather than capturing true polygenic signal." However, GWAS signals are overwhelmingly in LD with other common variants, not rare variants. LD between common GWAS SNPs and rare causal variants is typically minimal unless there is specific haplotype structure (e.g., the ABCA7 base deletion). The extent to which GWAS signals represent LD-tagging of rare variants is gene-specific and not generalizable.

2. Collinearity problem
If conditional models include PRS and rare variant burden scores, high collinearity is guaranteed because rare variant carriers often have higher PRS by chance (particularly for ABCA7 where LD exists). Models may be unstable, and coefficient estimates will have high variance. The claimed improvement may be overfitting rather than real signal capture.

3. Variance explained ceiling
Current PRS explains approximately 5-7% of AD variance in European populations. Rare variants (TREM2, ABCA7, SORL1) collectively explain perhaps 1-2% additional variance. The conditional model targets residual variance after PRS, but this residual includes noise, measurement error, environmental factors, and unmeasured genetic effects. Improvement in variance explained may be marginal.

4. Mechanistic distinction claim is vague
The hypothesis states "mechanistically distinct from simple additive models" but then does not specify what the distinct mechanism is. If both rare variants and PRS affect amyloid processing, the "separable" biological pathway claim requires demonstration that rare variant effects operate independent of polygenic amyloid SNPs.

Potential Counter-Evidence

• Gamage et al. (2021) found that adding rare variant burden to PRS improved AUC by only ~0.02 (0.78 to 0.80) in a UK Biobank AD cohort—statistically significant but modest clinical utility
• Cruchaga et al. demonstrated that TREM2 R47H carriers have PRS distributions overlapping substantially with non-carriers, arguing against systematic LD-tagging
• Gene-based burden tests for ABCA7, SORL1, TREM2 show substantial locus heterogeneity (many private variants), making universal "burden scores" problematic

Falsification Experiments

Primary falsification: In an independent validation cohort, compare nested models:

• Model 1: PRS alone
• Model 2: Rare variant burden alone
• Model 3: Additive (PRS + burden)
• Model 4: Conditional (PRS | burden, or interaction term)

If Model 3 (additive) explains as much variance as Model 4 (conditional), the interaction/conditional component is unnecessary and the "distinct mechanism" claim is falsified. Significant improvement of Model 4 over Model 3 is required to support the hypothesis.

Secondary test: Use simulation studies with known true architecture (specified effect sizes for polygenic SNPs and rare variants, with/without LD tagging) to determine whether the conditional model recovers true architecture or is biased by overfitting. If the model systematically overestimates rare variant effects due to LD confounding, the hypothesis is falsified.

Tertiary test: Examine whether conditional improvement is consistent across genes. If ABCA7 rare variant burden improves PRS but TREM2/SORL1 burden does not, the generalizable "LD-tagging" explanation fails and gene-specific mechanisms must be invoked.

Revised Confidence: 0.65

Upgraded from 0.70. The hypothesis is methodologically well-specified and addresses a genuine limitation of current PRS models. The empirical evidence is mixed but suggests modest improvement is achievable. Confidence slightly reduced due to collinearity concerns and the variance explained ceiling problem, but this remains the most tractable of the seven hypotheses.

Hypothesis 5: Stage-Specific Pathway PRS Accuracy

Specific Weaknesses

**1. Pathway

Practical Feasibility Assessment: Drug Development & Therapeutic Translation

Hypothesis 4: Conditional Rare Variant Burden Model

Confidence: 0.65 — Most tractable for immediate development

Druggability Assessment

Primary drug targets derived from this model:

| Gene | Function | Druggability | Target Validation Status |
|------|----------|--------------|-------------------------|
| TREM2 | Microglial survival/activation | ★★★★★ | Highly validated — antibodies in Phase II (AL002) |
| ABCA7 | Lipid transport/amyloid clearance | ★★☆☆ | Preclinical — small molecule modulators in development |
| SORL1 | Retromer trafficking of APP | ★★★☆☆ | Emerging target — no approved modulators yet |

Therapeutic Potential: HIGH for biomarker stratification, MODERATE for direct intervention

This hypothesis is fundamentally a stratification tool, not a direct therapeutic target. However, it identifies patients who would respond differentially to:

• Anti-amyloid immunotherapies (Aducanumab, Lecanemab, Donanemab)
• TREM2-targeting microglial modulators
• ABCA7-modulating lipid metabolism agents

Existing Compounds & Clinical Trials:

TREM2 modulators:

• AL002 (Alector/AbbVie) — Phase II for AD (NCT04592874)
• Other TREM2 agonists in Phase I

Lipid metabolism modifiers:

• Liver X Receptor (LXR) agonists — failed due to hepatotoxicity; ABCA7-specific modulators in preclinical
• PPAR agonists (fenofibrate) — repurposed, currently in Phase II for AD (NCT03302208)

Retromer function enhancers:

• Sorl1 has no direct modulators; indirect enhancement via retromer stabilizer (sorLA signaling)

Development Cost & Timeline:

| Milestone | Estimated Cost | Timeline |
|-----------|----------------|----------|
| Genetic stratification biomarker validation | $2-5M | 18-24 months |
| Retrospective analysis of existing trial cohorts for H4 stratification | $500K-1M | 12 months |
| Prospective validation in ongoing Phase III trials | $3-8M | 24-36 months |
| CDx (companion diagnostic) development if stratification proven | $10-15M | 36-48 months |

Primary Risk: Collinearity between PRS and rare variant burden may limit clinical utility of conditional model over simple additive. Risk-adjusted NNV (Number Needed to Validate) approximately 200-400 based on effect sizes.

Hypothesis 5: Stage-Specific Pathway PRS Accuracy

Original Confidence: 0.62 — Moderately tractable

Druggability Assessment

Pathway-targeted therapeutic candidates:

Immune Pathway (INPP5D, SPI1, PLCG2) — Conversion from MCI to AD:

| Target | Mechanism | Drug Candidates | Development Stage |
|--------|-----------|-----------------|-------------------|
| PLCG2 | Membrane signaling in microglia | No direct inhibitors; PLCG2 agonists in preclinical | Preclinical |
| INPP5D (SHIP1) | Inhibitory phosphatase in microglia | SHIP1 inhibitors (e.g., AQX-1125) | Phase II for COPD, not AD |
| SPI1 (PU.1) | Transcription factor | Not directly druggable | Target validation only |

Therapeutic Potential: MODERATE to LOW for immunomodulation approach

Amyloid Pathway (APP/PSEN) — Preclinical amyloid prediction:

• BACE inhibitors (failed): verubecestat, atabecestat — liver toxicity/CVH
• γ-secretase modulators: semagacestat (failed)
• Active immunotherapy: AAB-003, GSK933776

Key Insight: The hypothesis suggests different PRS weights for different disease stages. This translates to:

• Preclinical screening: Amyloid-PET prediction, prioritizing anti-amyloid prevention trials
• MCI conversion: Immune pathway-weighted PRS, prioritizing microglial modulators

Existing Trials with relevant endpoints:

• DIAN-TU (autosomal dominant AD): longitudinal PRS substudies
• A4 Study (preclinical AD): amyloid pathway PRS correlates with eligibility
• API/Generation trials: APOE genotype stratification with PRS

Development Cost & Timeline:

• PRS pathway decomposition validation: $1-2M, 12-18 months
• Pathway-specific intervention trials: $50-100M per Phase III
• Repurposing existing anti-immune compounds: $15-30M, 36-48 months

Safety Concerns:

Microglial modulation: TREM2 agonists may cause cytokine release; SHIP1 inhibitors have unclear CNS penetration

Stage-specific intervention: Earlier intervention with amyloid-targeting agents may miss immune-mediated damage window

SPI1 targeting: Transcription factor modulation risks broad transcriptional changes

Hypothesis 3: Ancestral PRS Architecture Dissociation

Confidence: 0.52 — Important but underpowered

Druggability Assessment

Ethnically-differentiated therapeutic targets:

| Gene | Ancestry-Specific Burden | Therapeutic Implication |
|------|-------------------------|------------------------|
| ABCA7 | Enriched LOF in African ancestry | ABCA7 agonists may have differential efficacy |
| APOE | ε4 effect size varies by ancestry | Dosing stratification by genotype |
| ABCA1 | LOF variants with unclear AD risk | Lipid metabolism targets require ancestry matching |

Therapeutic Potential: MODERATE for equity, LOW for direct drug development

The primary value is clinical trial inclusion — African ancestry populations are systematically underrepresented in AD trials. A validated ancestry-adjusted PRS would:

• Improve enrollment equity
• Reduce type II error in underpowered subgroup analyses
• Enable precision medicine rollout to underserved populations

Existing Compounds:

• None ancestry-specific
• APOE-targeted approaches (e.g., APOE4-specific immunotherapy) currently European-only validation

Development Cost:

• African ancestry AD consortium genotyping: $3-5M
• PRS transferability validation: $2-4M
• Multi-ancestry trial protocol development: $1-2M per trial

Timeline: 36-60 months for adequate validation given recruitment challenges.

Critical Safety Concern: Ancestry-based stratification must not become a mechanism for unequal access to therapeutics. Any stratification must be paired with expanded access protocols.

Hypothesis 7: Metabolic AD Endophenotype

Confidence: 0.55 — Emerging hypothesis with strong biological plausibility

Druggability Assessment

Metabolic pathway targets:

| Gene/Pathway | Function | Drug Candidates | Status |
|--------------|----------|----------------|--------|
| IDE (insulin-degrading enzyme) | Aβ and insulin degradation | IDE modulators — not in AD pipeline | Preclinical only |
| AKT1/mTOR | Metabolic signaling | Rapamycin analogs, metformin | Repurposing candidates |
| Glucose metabolism | Brain energy failure | No direct targets; metabolic enhancers in Phase II | Limited |

Therapeutic Potential: MODERATE (repurposing) to LOW (de novo development)

Key Drugs:

Metformin: Large Type 2 diabetes population; AD prevention trials (NCT04098668, NCT02633678)

Rapamycin/mTOR inhibitors: mTOR inhibition extends lifespan in preclinical models; concerns about immunosuppression in elderly

GLP-1 agonists: Liraglutide in Phase II for AD (NCT01469351)

Development Cost & Timeline:

| Strategy | Cost | Timeline | Success Probability |
|----------|------|----------|---------------------|
| Metformin repurposing for metabolic AD | $10-20M | 48-60 months | 25-35% (mechanism unclear) |
| GLP-1 agonist repurposing | $30-50M | 60-72 months | 30-40% |
| IDE agonist development | $200M+ | 10+ years | Unknown |

Safety Concerns:

Metformin: Generally safe; lactic acidosis risk in renal impairment; GI side effects

Rapamycin: Immunosuppression, metabolic syndrome, wound healing — high risk for elderly population

Metabolic subtype definition: Cannot identify metabolic endophenotype without amyloid PET + FDG-PET + genetics; high diagnostic cost ($5,000-8,000 per subject)

Critical Unknown: The hypothesis claims this subtype will be "reduced responsiveness to anti-amyloid therapies." This requires prospective validation in patients treated with lecanemab/donanemab. If confirmed, metabolic pathway drugs become priority combination therapy.

Hypothesis 6: Polygenic Cognitive Reserve

Confidence: 0.58 — Highest theoretical interest, lowest near-term tractability

Druggability Assessment

Neuroprotective pathway targets:

| Gene/Pathway | Mechanism | Drug Candidates | Stage |
|--------------|-----------|-----------------|-------|
| BDNF pathway | Synaptic plasticity, neurogenesis | BDNF mimetics (TrkB agonists) | Phase I for depression |
| COMT | Prefrontal efficiency | None — enzyme too broad | Research only |
| NTRK2 (TrkB) | Neurotrophic signaling | TrkB agonists (NGF mimetics) | Preclinical |

Therapeutic Potential: LOW to MODERATE (long-term)

This hypothesis identifies a resilience modifier that could potentially be pharmacologically enhanced:

TrkB agonists: Activate BDNF signaling; no approved CNS-active compounds

Mitochondrial enhancers: Target neuroprotective polygenic effects on energy metabolism

Synaptic plasticity enhancers:CAMK2 pathway modulators

Existing Compounds:

• 7,8-DHF (TrkB agonist): Preclinical only
• P7C3-class compounds (nicotinamide phosphoribosyltransferase activators): Preclinical neurogenesis
• No COMT inhibitors in development for CNS purposes

Development Barriers:

• Polygenic score integration: Too many variants with tiny effects to drug individually
• Pathway vs. single target: Would require multi-target intervention
• Measurement challenge: Cognitive reserve cannot be measured directly; proxy endpoints are insufficient

Safety Concerns: Neurotrophic factor enhancement risks:

• Neuronal overgrowth/tumorigenesis
• Seizure risk (BDNF signaling)
• Unknown long-term effects on neural circuitry

Consolidated Priority Ranking for Drug Development

| Rank | Hypothesis | Development Stage | Investment Required | Time to Value | Risk-Adjusted ROI Potential |
|------|------------|-------------------|---------------------|---------------|----------------------------|
| 1 | H4 (Conditional rare variant + PRS) | Biomarker validation | $5-15M | 24-48 months | ★★★★☆ |
| 2 | H5 (Stage-specific pathway PRS) | Target identification | $15-30M | 36-60 months | ★★★☆☆ |
| 3 | H7 (Metabolic endophenotype) | Repurposing validation | $20-40M | 48-60 months | ★★★☆☆ |
| 4 | H3 (Ancestral PRS architecture) | Equity infrastructure | $5-10M | 36-60 months | ★★★☆☆ (social value high) |
| 5 | H6 (Cognitive reserve) | Basic research | $100M+ | 10+ years | ★★☆☆☆ |

Immediate Action Items

H4 validation in existing anti-amyloid trial datasets (Aduhelm, Lecanemab) — highest priority given existing investment in those trials and availability of genetic data

H5 pathway decomposition using ADNI/BNI data — relatively low cost ($500K) to test immune vs. amyloid pathway PRS weights against MCI conversion endpoints

H7 prospective metabolic subtyping — embed FDG-PET + genetic panel into ongoing prevention trials; incremental cost $500-1,000/subject for imaging

H3 African ancestry enrollment expansion — policy/recruitment issue rather than drug development; return on investment measured in equity terms

H6 — place on long-term research funding only; do not commit to clinical development given target tractability barriers

Domain Expert Assessment: Practical Feasibility of AD Rare Variant + PRS Hypotheses

Executive Summary

Most hypotheses address prediction/diagnostic stratification rather than direct therapeutic targets. Only Hypotheses 4 and 7 have meaningful therapeutic implications. The field faces fundamental tension: hypotheses generating the highest therapeutic interest (H4) suffer from the most severe power limitations, while statistically tractable hypotheses (H1, H5) offer minimal therapeutic utility.

Hypothesis 1: Synergistic Epistasis Rare Variants + PRS

Revised Confidence: 0.48

Druggability Assessment

| Dimension | Assessment |
|-----------|------------|
| Direct therapeutic target | No – interaction effect between genotypes is not inherently druggable |
| Stratification utility | Moderate – could inform PRS recalibration by rare variant carrier status |
| Drug development pathway | None identifiable |

Biological Mechanism

• "Multiplicative enhancement" lacks molecular specification – no defined pathway to intervene
• PRS already captures inflammatory/microglial common variant burden
• PLCG2 contradiction (protective AND amplifying risk) indicates unrefined hypothesis

Practical Verdict

Not feasible for therapeutic development. This is a statistical/epidemiological hypothesis at current sample sizes. The interaction effect, even if real, cannot be therapeutically modulated given current understanding. If validated, it would only inform risk prediction, not intervention.

Hypothesis 2: Synaptic Rare Variant Burden in EOAD

Revised Confidence: 0.45

Druggability Assessment

| Dimension | Assessment |
|-----------|------------|
| Direct therapeutic target | No – essential synaptic genes (SNAP25, SYT1) are not druggable |
| Stratification utility | Low – monogenic EOAD already identifiable via established panels |
| Drug development pathway | None |

Critical Issues

Gene selection undefined – without pre-specified gene set, burden test is unfalsifiable

Essential gene paradox – highly penetrant synaptic variants causing late-onset neurodegeneration are biologically implausible; most pathogenic variants would manifest as neurodevelopmental phenotypes

Conflation of EOAD subtypes – familial monogenic forms are not "missing heritability"

Practical Verdict

Not feasible. The hypothesis fundamentally misunderstands EOAD genetics. Established monogenic causes (PSEN1/2, APP) explain the heritability difference. Sporadic EOAD after excluding these shows no significant synaptic gene enrichment in sequencing studies. No actionable therapeutic target emerges.

Hypothesis 3: Ancestral Rare Variant Architecture

Revised Confidence: 0.52

Druggability Assessment

| Dimension | Assessment |
|-----------|------------|
| Direct therapeutic target | No – PRS accuracy hypothesis, not mechanism hypothesis |
| Stratification utility | Moderate – improved PRS for underrepresented populations |
| Drug development pathway | None directly, but informs inclusion strategy |

Practical Considerations

• Addresses genuine clinical need: PRS performs poorly in non-European populations
• However, the proposed mechanism (population-specific rare variants) explains only a fraction of PRS portability reduction
• Structural GWAS issues (LD reference panels, SNP weight calibration) likely contribute more than rare variant burden
• Therapeutic potential is entirely indirect (better risk stratification enabling earlier intervention)

Compounds/Trials

None relevant – this is a diagnostic/prediction refinement, not a target identification exercise.

Practical Verdict

Limited therapeutic feasibility. The hypothesis identifies a valid clinical problem but proposes an unproven mechanism. Even if validated, it would improve prediction algorithms, not identify new drug targets. Development pathway: improved PRS methodology, not compound development.

Hypothesis 4: Protective Rare Variants in PRS Non-Responders

Revised Confidence: 0.55 (highest therapeutic potential)

Druggability Assessment

| Dimension | Assessment |
|-----------|------------|
| Direct therapeutic target | Partial – identifies microglial amyloid clearance as therapeutic goal |
| Mechanism | Potentially druggable – enhanced microglial function is targetable |
| Therapeutic angle | Agonism/mimicry of protective variant effects |

Proposed Drug Development Pathway

Target Identification:

• PLCG2 P522R (protective) → enhanced phospholipase activity → microglial survival signaling
• TREM2 gain-of-function variants → enhanced amyloid binding/clearance

Therapeutic Strategies:

Small molecule agonists of TREM2 signaling pathway

Biologic agents (antibodies, fusion proteins) mimicking TREM2 activation

Downstream pathway modulators (DAP12/TYROBP signaling cascade)

Existing Compounds and Trials

| Agent | Status | Target/Mechanism |
|-------|--------|------------------|
| AL002 (Alector) | Phase 2 (TREM2 agonist) | TREM2 activation for AD |
| BI 6942047 (Boehringer) | Phase 1 | TREM2 pathway |
| Genentech TREM2 programs | Preclinical | Microglial modulation |

Development Cost and Timeline

| Phase | Estimated Timeline | Estimated Cost |
|-------|-------------------|----------------|
| Target validation | 2-3 years | $15-30M |
| Lead optimization | 3-4 years | $40-80M |
| Phase 1/2 | 3-5 years | $50-100M |
| Phase 3 | 4-6 years | $200-400M |
| Total | 12-18 years | $300-600M |

Safety Concerns

Immune activation – TREM2 modulates macrophage/microglial activation;过度激活 could cause neuroinflammation

Off-target effects – TYROBP/DAP12 expressed in NK cells and osteoclasts

Dose-response complexity – microglial states are context-dependent (protective vs. damaging)

Variant-specificity risk – PLCG2 contains both protective (P522R) and risk-increasing (P268L) variants; pathway activation may not be uniformly beneficial

Falsification-Specific Challenge

The hypothesis requires identifying high-PRS cognitively intact elderly with rare variant sequencing – cohorts that essentially don't exist at necessary scale. The biological insight is valuable, but testing it requires prospective cohorts with germline sequencing and extended follow-up that won't exist for 10-15 years.

Practical Verdict

Highest therapeutic feasibility among all hypotheses, but with major timing constraints. The TREM2 agonist space is already being pursued by major pharma (Alector, Roche). The hypothesis provides mechanistic justification for this approach but does not substantially advance the field beyond ongoing programs.

Hypothesis 5: Temporal Threshold Model

Revised Confidence: 0.48

Druggability Assessment

| Dimension | Assessment |
|-----------|------------|
| Direct therapeutic target | No – model specification lacks biological mechanism |
| Stratification utility | Low – age-dependent thresholds are clinically used already (APOE ε4) |
| Drug development pathway | None |

Fundamental Problems

Model not specified – "inflection point of risk acceleration" has no operational definition

Testing strategy contradicts hypothesis – Cox PH assumes proportional hazards; threshold model violates this

"Any pathogenic rare variant" – unfalsifiably broad

Practical Verdict

Not actionable. Without a specified molecular mechanism or mathematical model, this cannot drive drug development. The insight (rare variants shift onset timing) is already utilized clinically (familial AD mutation carriers show earlier onset). No incremental therapeutic utility.

Hypothesis 6: Multi-Ancestry PRS + Rare Variant Burden

Revised Confidence: 0.58 (highest original confidence)

Druggability Assessment

| Dimension | Assessment |
|-----------|------------|
| Direct therapeutic target | No – prediction score, not mechanism |
| Stratification utility | Moderate – identifies high-risk individuals for existing interventions |
| Drug development pathway | None directly |

Therapeutic Utility

The hypothesis enables earlier identification of conversion risk from MCI to AD. This allows:

• Earlier deployment of existing drugs (cholinesterase inhibitors, anti-amyloid antibodies)
• More aggressive cardiovascular risk management
• Enhanced monitoring and planning

Target: Lipid Metabolism Genes

| Gene | Known Drug Targets | Status |
|------|-------------------|--------|
| ABCA7 | None direct | Research target |
| APOE | No direct agonist | Gene therapy approaches in preclinical |
| LDLR | Statins, PCSK9 inhibitors | Established cardiovascular drugs |

Practical Consideration

Lipid metabolism in AD is already aggressively targeted – statins, lifestyle modification, cardiovascular risk reduction are standard of care. The hypothesis would justify more aggressive lipid management in identified high-risk individuals, but this is not novel intervention, just optimized patient selection.

Practical Verdict

Prediction utility, not therapeutic innovation. No new drug targets identified. Provides marginal improvement over existing PRS for identifying conversion risk, enabling earlier deployment of current therapies.

Hypothesis 7: Endophenotype-Specific Prediction

Revised Confidence: 0.67 (highest revised confidence)

Druggability Assessment

| Dimension | Assessment |
|-----------|------------|
| Direct therapeutic target | Partial – pathway-specific predictions imply pathway-specific interventions |
| Mechanism | Druggable – microglial (TREM2/ABCA7) and synaptic (NLGN3, SHANK3) pathways have intervention potential |
| Therapeutic angle | Pathway-specific drug development guided by variant profiles |

Dual Pathway Framework

Pathway 1: Microglial/Amyloid Pathway

• Genes: TREM2, ABCA7
• Endophenotype: Amyloid PET positivity
• Therapeutic target: Microglial activation modulation (see H4)

Pathway 2: Synaptic/Cognitive Pathway

• Genes: NLGN3, SHANK3, CNTNAP2
• Endophenotype: Cognitive decline trajectory
• Therapeutic target: Synaptic stabilization/enhancement

Drug Development Implications

| Pathway | Therapeutic Strategy | Existing Compounds |
|---------|---------------------|-------------------|
| Microglial | TREM2 agonism, anti-inflammatory modulation | AL002, anti-inflammatory approaches |
| Synaptic | Synaptic stabilization, neuroprotection | Multiple candidates in development |

Clinical Trial Design Utility

The hypothesis provides mechanistic justification for pathway-specific trial enrichment:

• Rare TREM2/ABCA7 carriers → amyloid-targeted trials (anti-amyloid antibodies)
• Rare NLGN3/SHANK3 carriers → symptomatic/cognitive protection trials

Safety Concerns

Synaptic genes (NLGN3, SHANK3) are autism-associated; modulating these pathways risks psychiatric effects

CNTNAP2 variants linked to epilepsy and autism spectrum – pathway modulation could lower seizure threshold

Practical Verdict

Highest combined score for scientific rigor and therapeutic utility. Provides framework for:

More efficient clinical trial enrichment

Pathway-specific therapeutic development

Biomarker vs. clinical outcome dissociation explanation

The endophenotype-specific framework transforms these hypotheses from prediction refinements into drug development stratification tools.

Consolidated Feasibility Matrix

| Hypothesis | Therapeutic Target | Development Timeline | Estimated Cost | Safety Profile | Overall Feasibility |
|------------|--------------------|---------------------|----------------|----------------|---------------------|
| H1 | None (interaction not druggable) | N/A | N/A | N/A | Very Low |
| H2 | None (essential genes) | N/A | N/A | N/A | Very Low |
| H3 | None (prediction refinement) | 2-3 years | $5-10M | N/A | Low |
| H4 | TREM2 pathway agonist | 12-18 years | $300-600M | Moderate concern | Moderate-High |
| H5 | None (model only) | N/A | N/A | N/A | Very Low |
| H6 | None (prediction tool) | 2-3 years | $5-10M | N/A | Low |
| H7 | Pathway-specific (TREM2, synaptic) | 10-15 years | $200-500M | Psychiatric/seizure risk | Moderate |

Strategic Recommendations

Immediate Action (0-2 years)

H7 (endophenotype-specific) – Design clinical trial enrichment strategies based on pathway-specific rare variant profiles. Incorporate into existing phase 2/3 trial protocols as optional genotyping strata.

H4 (protective variants) – Leverage existing TREM2 agonist programs (AL002, BI 6942047) with biomarker stratification based on rare variant carrier status.

Medium-Term (2-5 years)

H3/H6 – Build multi-ancestry PRS incorporating rare variant burden for clinical risk stratification. Implement in diverse recruitment for prevention trials.

H4 validation – Establish prospective cohort of high-PRS elderly with germline sequencing and longitudinal cognitive assessment. Critical for validating protective variant hypothesis.

Development Caution

• Avoid H1, H2, H5 – fundamental methodological issues and lack of therapeutic targets make these poor investment targets
• H4 requires 10+ year horizon – even with positive validation, therapeutic development is lengthy
• H7 provides immediate utility – not as drug development but as trial design improvement

Gap Analysis

The critical bottleneck is deeply phenotyped elderly cohorts with whole-genome sequencing and extended longitudinal follow-up. This infrastructure is required to test H4 and is essentially nonexistent at the necessary scale. Investment in such cohorts (cost: $50-100M over 5-10 years) would enable testing multiple high-value hypotheses.